Drug Profile

LY 3056480

Alternative Names: LY3056480

Latest Information Update: 29 Aug 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Audion Therapeutics
Class Small molecules
Mechanism of Action Amyloid precursor protein secretase inhibitors; Notch signalling pathway inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

25 Aug 2022 Audion Therapeutics withdraws prior to enrolment a phase II VESTA trial in Sensorineural hearing loss (In adults, In the elderly) in USA (Intratympanic, Injection)(NCT05061758)
30 Sep 2021 Audion Therapeutics plans the phase II VESTA trial for Sensorineural hearing loss (In adults, In the elderly) in USA (Intratympanic, Injection) in September 2022 (NCT05061758)
28 Sep 2020 Phase I/II clinical trials ongoing in Sensorineural hearing loss (In adults, In the elderly) in Greece, Germany, United Kingdom (Intratympanic) (EudraCT2016-004544-10)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com